Literature DB >> 2443529

Quantitation and antigenic characterization of bound C3 of circulating immune complexes in systemic lupus erythematosus, rheumatoid arthritis, and primary biliary cirrhosis.

B Nilsson1, A Bjelle, L Lööf, U R Nilsson.   

Abstract

In recent years defective function of the complement-mediated clearance of immune complexes (IC) has been reported in patients with immune complex disease. The defect has been found at different levels in the clearance system. An important event in this sequential system is the binding of C3-coated particles to C3 receptors on erythrocytes and phagocytes. This study focuses on immunochemical properties of IC-bound C3 that reflect the functional state of the molecule. Sera from patients with primary biliary cirrhosis (PBC), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE) and from normal subjects were analyzed for their level of C3 precipitable in 2.7% (w/v) polyethylene glycol (PEG). The mean levels for the patient categories were significantly higher than that for the normal subjects. The immunochemical study revealed several differences among the different forms of PEG-precipitable C3. All forms expressed C3(D) antigens which are expressed by immune complex-associated and denatured forms but not by soluble physiological forms of C3. The expression of these antigens was proportionately lower for the complex-associated C3 of PBC compared to that of RA and SLE. Furthermore, employing monoclonal anti-C3(D) antibodies against the C3c and the C3d domain, distinct differences could be detected among all forms of PEG-precipitable C3. Sera from RA and SLE, in particular, contained PEG-precipitable C3 that exhibited distinctive immunochemical features with respect to these epitopes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2443529     DOI: 10.1007/bf00917020

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  15 in total

1.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

2.  SDS denaturation of complement factor C3 as a model for allosteric modifications occurring during C3b binding: demonstration of a profound conformational change by means of circular dichroism and quantitative immunoprecipitation.

Authors:  B Nilsson; U R Nilsson
Journal:  Immunol Lett       Date:  1986-08       Impact factor: 3.685

Review 3.  The role of complement and its receptor in the elimination of immune complexes.

Authors:  J A Schifferli; Y C Ng; D K Peters
Journal:  N Engl J Med       Date:  1986-08-21       Impact factor: 91.245

Review 4.  Immune complex disease.

Authors:  K Kano; F Milgrom
Journal:  Vox Sang       Date:  1980       Impact factor: 2.144

5.  Maturation of the head of bacteriophage T4. I. DNA packaging events.

Authors:  U K Laemmli; M Favre
Journal:  J Mol Biol       Date:  1973-11-15       Impact factor: 5.469

6.  Primary biliary cirrhosis.

Authors:  P Scheuer
Journal:  Proc R Soc Med       Date:  1967-12

7.  Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.

Authors:  M T Aguado; J D Lambris; G C Tsokos; R Burger; D Bitter-Suermann; J D Tamerius; F J Dixon; A N Theofilopoulos
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

8.  Analogous antigenic alterations elicited in C3 by physiologic binding and by denaturation in the presence of sodium dodecylsulfate.

Authors:  U R Nilsson; B Nilsson
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

9.  Identification of a nonproteolytically activated C3 with CR 1-binding properties in sera from subjects with primary biliary cirrhosis.

Authors:  B Nilsson; L Lööf; U R Nilsson
Journal:  Int Arch Allergy Appl Immunol       Date:  1986

10.  Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies.

Authors:  P J Lachmann; M K Pangburn; R G Oldroyd
Journal:  J Exp Med       Date:  1982-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.